Phathom

Quote








Takeda has already moved their position. Most of our shares are held by 3 large equity firms.

Bottom line, we aren't moving the needle with this product. Shame, because there are patients out there who could benefit but we simply don't have the managed care juice to get any access and this is an access driven molecule.

Hope we can get a double digits buy out. $11 a share would be a win.
 




anonymous said:
Takeda has already moved their position. Most of our shares are held by 3 large equity firms.

Bottom line, we aren't moving the needle with this product. Shame, because there are patients out there who could benefit but we simply don't have the managed care juice to get any access and this is an access driven molecule.

Hope we can get a double digits buy out. $11 a share would be a win.
Click to expand...
Not an employee but an investor. Do you think someone is running down the price to buy the molecule? I’m unfortunately familiar with GERD and plan to ask my GI for your product after my endoscopy. The product should be a win, but the field knows if or how many RXs make it thru the prior authorization process. I did ask my GI about that as well, he said a recent endoscopy should show medical need (hopefully for me, not). I take Dupixent 2x a day now, regularly feel it’s not working. TIA for any information or tips on how to get my prescription once the order is written.
 




anonymous said:
Takeda has already moved their position. Most of our shares are held by 3 large equity firms.

Bottom line, we aren't moving the needle with this product. Shame, because there are patients out there who could benefit but we simply don't have the managed care juice to get any access and this is an access driven molecule.

Hope we can get a double digits buy out. $11 a share would be a win.
Click to expand...

another ill informed peasant talking with so much knowledge. First quarter into launch and making statements like “not moving the needle” GTFO of here. HR really messed up the hiring of so many terrible reps that know nothing other then how to complain. idiots.
 




There is some validity to the high number of subpar reps. Not sure if it’s because of the low salary cap but half of the reps are definitely underwhelming in the talent area. Plus capped commission… what the hell.
 




anonymous said:
another ill informed peasant talking with so much knowledge. First quarter into launch and making statements like “not moving the needle” GTFO of here. HR really messed up the hiring of so many terrible reps that know nothing other then how to complain. idiots.
Click to expand...

if you cant tell that most of these posts are trolls/shorts then i dont know what to tell you! Kind of pathetic that you keep getting baited. Also go ahead and act like you are all knowing but our stock is pointing straight down because wall street has zero confidence in leadership like yourself! Perhaps you dont know it all either…south of 4 dollars soon
 




anonymous said:
if you cant tell that most of these posts are trolls/shorts then i dont know what to tell you! Kind of pathetic that you keep getting baited. Also go ahead and act like you are all knowing but our stock is pointing straight down because wall street has zero confidence in leadership like yourself! Perhaps you dont know it all either…south of 4 dollars soon
Click to expand...

LOSER
 




anonymous said:
Takeda has already moved their position. Most of our shares are held by 3 large equity firms.

Bottom line, we aren't moving the needle with this product. Shame, because there are patients out there who could benefit but we simply don't have the managed care juice to get any access and this is an access driven molecule.

Hope we can get a double digits buy out. $11 a share would be a win.
Click to expand...
11 would be a miracle at this point
 
















































Top Bottom
Back
Quote